SLC2A1 and neoplasm: Glycolysis inhibitors including STF-31 (a small molecule inhibitor of GLUT1)31, Fasentin (inhibition of GLUT1/GLUT4)32 and BAY-876 (an ATP inhibitor)31 have shown satisfactory results in the tumor-bearing mouse models.